Mayo Clinic
Alexander C. Gun
The purpose of this study is to compare changes in RV structure and function, biomarkers, and patient reported outcomes between TOF patients randomized to an ARNI vs placebo.
Tetralogy of Fallot
Ebstein's Anomaly
Entresto Pill
Placebo
PHASE3
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 45 participants |
Masking : | DOUBLE |
Primary Purpose : | TREATMENT |
Official Title : | Role of Sacubitril-Valsartan for Right Ventricular Reverse Remodeling in Adults with Tetralogy of Fallot and Ebstein's Anomaly: a Randomized Controlled Pilot Clinical Trial |
Actual Study Start Date : | 2024-12 |
Estimated Primary Completion Date : | 2026-12 |
Estimated Study Completion Date : | 2026-12 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905